Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects.

Purpose: Dexmedetomidine is an α-adrenoceptor agonist used for perioperative and intensive care sedation. This study develops mechanism-based population pharmacokinetic-pharmacodynamic models for the cardiovascular and central nervous system (CNS) effects of intravenously (IV) and intranasally (IN)...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Clinical Pharmacology Vol. 71; no. 10; pp. 1197 - 1208
Autores principales: Yoo, Heedoo, Iirola, Timo, Vilo, Sanna, Manner, Tuula, Aantaa, Riku, Lahtinen, Maria, Scheinin, Mika, Olkkola, Klaus, Jusko, William
Formato: equations & formulas research tables/charts randomized controlled trial Journal Article
Publicado: Springer Nature Oct2015
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109345390&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 109345390
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00316970
        NP9
      jtl: European Journal of Clinical Pharmacology
      issn: 00316970
      maglogo: N
    pubinfo:
      dt: Oct2015
      vid: 71
      iid: 10
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        109345390
        109345390
        109345390
        10.1007/s00228-015-1913-0
        109345390
      ppf: 1197
      ppct: 11
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects.
      aug:
        au:
          Yoo, Heedoo
          Iirola, Timo
          Vilo, Sanna
          Manner, Tuula
          Aantaa, Riku
          Lahtinen, Maria
          Scheinin, Mika
          Olkkola, Klaus
          Jusko, William
        affil: Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, 404 Kapoor Hall, State University of New York at Buffalo, Buffalo 14214 USA
      sug:
        subj:
          Imidazoles Pharmacokinetics
          Imidazoles Pharmacodynamics
          Imidazoles Administration and Dosage
          Administration, Intravenous
          Hypnotics and Sedatives Administration and Dosage
          Human
          Male
          Imidazoles Blood
          Norepinephrine Blood
          Epinephrine Blood
          Biological Availability
          Descriptive Statistics
          Cardiovascular System Drug Effects
          Central Nervous System Drug Effects
          Secondary Analysis
          Adolescence
          Young Adult
          Data Analysis Software
          Randomized Controlled Trials
          Crossover Design
          Hemodynamics
          Visual Analog Scaling
          Funding Source
          Adolescent: 13-18 years
          Male
      ab: Purpose: Dexmedetomidine is an α-adrenoceptor agonist used for perioperative and intensive care sedation. This study develops mechanism-based population pharmacokinetic-pharmacodynamic models for the cardiovascular and central nervous system (CNS) effects of intravenously (IV) and intranasally (IN) administered dexmedetomidine in healthy subjects. Method: Single doses of 84 μg of dexmedetomidine were given once IV and once IN to six healthy men. Plasma dexmedetomidine concentrations were measured for 10 h along with plasma concentrations of norepinephrine (NE) and epinephrine (E). Blood pressure, heart rate, and CNS drug effects (three visual analog scales and bispectral index) were monitored to assess the pharmacological effects of dexmedetomidine. PK-PD modeling was performed for recently published data (Eur J Clin Pharmacol 67: 825, 2011). Results: Pharmacokinetic profiles for both IV and IN doses of dexmedetomidine were well fitted using a two-compartment PK model. Intranasal bioavailability was 82 %. Dexmedetomidine inhibited the release of NE and E to induce their decline in blood. This decrease in NE was captured with an indirect response model. The concentrations of the mediator NE served via a biophase/transduction step and nonlinear pharmacologic functions to produce reductions in blood pressure and heart rate, while a direct effect model was used for the CNS effects. Conclusion: The comprehensive panel of two biomarkers and seven response measures were well captured by the population PK/PD models. The subjects were more sensitive to the CNS (lower EC values) than cardiovascular effects of dexmedetomidine.
      pubtype: Academic Journal
      doctype:
        equations & formulas
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N